Actinium Pharmaceuticals Inc. (ATNM) Downgraded to Hold at Zacks Investment Research
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
Other research analysts also recently issued research reports about the stock. FBR & Co set a $9.00 price objective on shares of Actinium Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, July 21st. Roth Capital began coverage on shares of Actinium Pharmaceuticals in a research report on Thursday, August 25th. They issued a buy rating and a $5.00 price objective on the stock.
Shares of Actinium Pharmaceuticals (NYSEMKT:ATNM) opened at 1.16 on Tuesday. Actinium Pharmaceuticals has a one year low of $1.12 and a one year high of $3.50. The stock’s market cap is $55.35 million. The firm has a 50-day moving average of $1.62 and a 200-day moving average of $1.77.
In other Actinium Pharmaceuticals news, major shareholder Sloan-Kettering Cance Memorial sold 192,927 shares of the business’s stock in a transaction that occurred on Wednesday, August 31st. The shares were sold at an average price of $1.83, for a total transaction of $353,056.41. Following the sale, the insider now owns 4,878,988 shares of the company’s stock, valued at approximately $8,928,548.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
A number of hedge funds have recently made changes to their positions in ATNM. BlackRock Fund Advisors boosted its stake in shares of Actinium Pharmaceuticals by 31.5% in the second quarter. BlackRock Fund Advisors now owns 102,003 shares of the company’s stock valued at $181,000 after buying an additional 24,453 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Actinium Pharmaceuticals by 11.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 462,683 shares of the company’s stock valued at $819,000 after buying an additional 47,131 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter valued at approximately $247,000. Finally, Vanguard Group Inc. boosted its stake in shares of Actinium Pharmaceuticals by 19.2% in the second quarter. Vanguard Group Inc. now owns 1,581,228 shares of the company’s stock valued at $2,798,000 after buying an additional 254,318 shares during the last quarter.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.